{"id":77757,"date":"2026-09-01T12:31:45","date_gmt":"2026-09-01T04:31:45","guid":{"rendered":"https:\/\/flcube.com\/?p=77757"},"modified":"2026-09-01T12:31:46","modified_gmt":"2026-09-01T04:31:46","slug":"eisai-launches-leqembi-iqlik-subcutaneous-auto-injector-for-early-alzheimers-disease-in-the-united-states","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=77757","title":{"rendered":"Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer&#8217;s Disease in the United States"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Eisai Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/4523:TYO\">TYO: 4523<\/a>)<\/strong> announced that <strong>LEQEMBI IQLIK<\/strong>, a subcutaneous auto-injector formulation of <strong>lecanemab<\/strong>, has been launched in the <strong>United States<\/strong> for the initial treatment of adults with <strong>early Alzheimer&#8217;s disease (AD)<\/strong>, including mild cognitive impairment (MCI) or mild dementia due to AD (collectively referred to as early AD). The launch converts <strong>LEQEMBI<\/strong> therapy from clinic-based intravenous infusion into an at-home option \u2014 a pivotal step in broadening patient access to amyloid-directed treatment for <strong>Alzheimer&#8217;s disease<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-amp-launch-timeline\" class=\"wp-block-heading\">Regulatory &amp; Launch Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Date<\/th><th>Milestone<\/th><\/tr><\/thead><tbody><tr><td><strong>2025<\/strong><\/td><td>Approval and launch of the <strong>maintenance therapy<\/strong> indication for early AD<\/td><\/tr><tr><td><strong>Jul 2026<\/strong><\/td><td>US approval of <strong>LEQEMBI IQLIK<\/strong> for initial treatment of early AD<\/td><\/tr><tr><td><strong>01 Sep 2026<\/strong><\/td><td>US launch of <strong>LEQEMBI IQLIK<\/strong> subcutaneous auto-injector for initial treatment of early AD<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-administration\" class=\"wp-block-heading\">Drug Profile &amp; Administration<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Lecanemab<\/strong>, an anti-amyloid monoclonal antibody for <strong>early Alzheimer&#8217;s disease<\/strong><\/li>\n\n\n\n<li><strong>Formulation:<\/strong> <strong>LEQEMBI IQLIK<\/strong> \u2014 subcutaneous auto-injector, replacing intravenous infusion for eligible patients<\/li>\n\n\n\n<li><strong>Patient Benefits:<\/strong> Reduced administration time versus IV infusion and the option for <strong>at-home dosing<\/strong>, lowering the treatment burden on patients and caregivers<\/li>\n\n\n\n<li><strong>Coverage Across Treatment Journey:<\/strong> With initial treatment (2026 approval) and maintenance therapy (2025 approval) indications, <strong>LEQEMBI IQLIK<\/strong> spans the full treatment arc of early AD<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-eisai-biogen-collaboration-structure\" class=\"wp-block-heading\">Eisai\u2013Biogen Collaboration Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Partners<\/td><td><strong>Eisai Co., Ltd.<\/strong> and <strong>Biogen<\/strong><\/td><\/tr><tr><td>Global Development &amp; Regulatory Submissions<\/td><td><strong>Eisai<\/strong> (lead responsibility)<\/td><\/tr><tr><td>Commercialization<\/td><td>Co-commercialized by both companies<\/td><\/tr><tr><td>Final Decision-Making Authority<\/td><td><strong>Eisai<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Access Expansion:<\/strong> At-home subcutaneous dosing removes a major adoption barrier for <strong>LEQEMBI<\/strong> \u2014 repeated IV infusions \u2014 potentially widening the addressable early-AD patient population in the <strong>United States<\/strong><\/li>\n\n\n\n<li><strong>Franchise Durability:<\/strong> The full-indication arc from initial treatment through maintenance therapy strengthens <strong>LEQEMBI<\/strong>&#8216;s position as a complete, long-term treatment platform rather than a single intervention<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> As amyloid-directed therapies compete for diagnosis-driven market share, administration convenience becomes a decisive differentiator for <strong>Eisai<\/strong> and <strong>Biogen<\/strong> against rival anti-amyloid programs<\/li>\n\n\n\n<li><strong>Infrastructure Shift:<\/strong> Home dosing could reduce dependence on infusion-center capacity, easing healthcare-system bottlenecks that have constrained Alzheimer&#8217;s treatment volume<\/li>\n\n\n\n<li><strong>Catalyst Watch:<\/strong> Early uptake metrics, real-world adherence under home administration, and payer coverage policies will define the commercial trajectory of <strong>LEQEMBI IQLIK<\/strong><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2014 This brief contains forward-looking statements regarding product launch, market adoption, and commercial potential that involve risks and uncertainties. Actual results may differ materially. Nothing herein constitutes investment advice.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eisai Co., Ltd. (TYO: 4523) announced that LEQEMBI IQLIK, a subcutaneous auto-injector formulation of lecanemab,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":77758,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[350,40,1151],"class_list":["post-77757","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-eisai","tag-market-launch","tag-tyo-4523"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer&#039;s Disease in the United States - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eisai Co., Ltd. (TYO: 4523) announced that LEQEMBI IQLIK, a subcutaneous auto-injector formulation of lecanemab, has been launched in the United States for the initial treatment of adults with early Alzheimer&#039;s disease (AD), including mild cognitive impairment (MCI) or mild dementia due to AD (collectively referred to as early AD). The launch converts LEQEMBI therapy from clinic-based intravenous infusion into an at-home option \u2014 a pivotal step in broadening patient access to amyloid-directed treatment for Alzheimer&#039;s disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=77757\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer&#039;s Disease in the United States\" \/>\n<meta property=\"og:description\" content=\"Eisai Co., Ltd. (TYO: 4523) announced that LEQEMBI IQLIK, a subcutaneous auto-injector formulation of lecanemab, has been launched in the United States for the initial treatment of adults with early Alzheimer&#039;s disease (AD), including mild cognitive impairment (MCI) or mild dementia due to AD (collectively referred to as early AD). The launch converts LEQEMBI therapy from clinic-based intravenous infusion into an at-home option \u2014 a pivotal step in broadening patient access to amyloid-directed treatment for Alzheimer&#039;s disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=77757\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T04:31:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-01T04:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0102.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77757#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77757\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer&#8217;s Disease in the United States\",\"datePublished\":\"2026-09-01T04:31:45+00:00\",\"dateModified\":\"2026-09-01T04:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77757\"},\"wordCount\":392,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77757#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/0102.webp\",\"keywords\":[\"Eisai\",\"Market launch\",\"TYO: 4523\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77757#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77757\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=77757\",\"name\":\"Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer's Disease in the United States - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77757#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77757#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/0102.webp\",\"datePublished\":\"2026-09-01T04:31:45+00:00\",\"dateModified\":\"2026-09-01T04:31:46+00:00\",\"description\":\"Eisai Co., Ltd. (TYO: 4523) announced that LEQEMBI IQLIK, a subcutaneous auto-injector formulation of lecanemab, has been launched in the United States for the initial treatment of adults with early Alzheimer's disease (AD), including mild cognitive impairment (MCI) or mild dementia due to AD (collectively referred to as early AD). The launch converts LEQEMBI therapy from clinic-based intravenous infusion into an at-home option \u2014 a pivotal step in broadening patient access to amyloid-directed treatment for Alzheimer's disease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77757#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77757\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77757#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/0102.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/0102.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer's Disease in the United States\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77757#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer&#8217;s Disease in the United States\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer's Disease in the United States - Insight, China&#039;s Pharmaceutical Industry","description":"Eisai Co., Ltd. (TYO: 4523) announced that LEQEMBI IQLIK, a subcutaneous auto-injector formulation of lecanemab, has been launched in the United States for the initial treatment of adults with early Alzheimer's disease (AD), including mild cognitive impairment (MCI) or mild dementia due to AD (collectively referred to as early AD). The launch converts LEQEMBI therapy from clinic-based intravenous infusion into an at-home option \u2014 a pivotal step in broadening patient access to amyloid-directed treatment for Alzheimer's disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=77757","og_locale":"en_US","og_type":"article","og_title":"Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer's Disease in the United States","og_description":"Eisai Co., Ltd. (TYO: 4523) announced that LEQEMBI IQLIK, a subcutaneous auto-injector formulation of lecanemab, has been launched in the United States for the initial treatment of adults with early Alzheimer's disease (AD), including mild cognitive impairment (MCI) or mild dementia due to AD (collectively referred to as early AD). The launch converts LEQEMBI therapy from clinic-based intravenous infusion into an at-home option \u2014 a pivotal step in broadening patient access to amyloid-directed treatment for Alzheimer's disease.","og_url":"https:\/\/flcube.com\/?p=77757","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-01T04:31:45+00:00","article_modified_time":"2026-09-01T04:31:46+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0102.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=77757#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=77757"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer&#8217;s Disease in the United States","datePublished":"2026-09-01T04:31:45+00:00","dateModified":"2026-09-01T04:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=77757"},"wordCount":392,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=77757#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0102.webp","keywords":["Eisai","Market launch","TYO: 4523"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=77757#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=77757","url":"https:\/\/flcube.com\/?p=77757","name":"Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer's Disease in the United States - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=77757#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=77757#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0102.webp","datePublished":"2026-09-01T04:31:45+00:00","dateModified":"2026-09-01T04:31:46+00:00","description":"Eisai Co., Ltd. (TYO: 4523) announced that LEQEMBI IQLIK, a subcutaneous auto-injector formulation of lecanemab, has been launched in the United States for the initial treatment of adults with early Alzheimer's disease (AD), including mild cognitive impairment (MCI) or mild dementia due to AD (collectively referred to as early AD). The launch converts LEQEMBI therapy from clinic-based intravenous infusion into an at-home option \u2014 a pivotal step in broadening patient access to amyloid-directed treatment for Alzheimer's disease.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=77757#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=77757"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=77757#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0102.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0102.webp","width":1080,"height":608,"caption":"Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer's Disease in the United States"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=77757#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eisai Launches LEQEMBI IQLIK Subcutaneous Auto-Injector for Early Alzheimer&#8217;s Disease in the United States"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0102.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77757","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=77757"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77757\/revisions"}],"predecessor-version":[{"id":77759,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77757\/revisions\/77759"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/77758"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=77757"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=77757"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=77757"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}